Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial empirical antimicrobial therapy: duration and subsequent modifications.

K Tamura1

  • 1Fukuoka University Hospital, Fukuoka, Japan. ktamura@fukuoka-u.ac.jp

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|July 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Escherichia coli tRNA(Asp) recognition mechanism differing from that of the yeast system.

Biochemical and biophysical research communications·1992
Same author

Toxic effects of oxygen-derived free radicals on rat pancreatic acini; an in vitro study.

Hepato-gastroenterology·1992
Same author

[A 52-week oral chronic toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethanesulfonate (FUT-187) in rats with a recovery period of 5 weeks.

The Journal of toxicological sciences·1992
Same author

[A 13-week subacute oral toxicity study of 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethanesulfonate (FUT-187) in rats].

The Journal of toxicological sciences·1992
Same author

Mixed connective tissue disease associated with protein losing enteropathy: successful treatment with intravenous cyclophosphamide therapy.

Internal medicine (Tokyo, Japan)·1992
Same author

Localized, aggregative, and diffuse adherence to HeLa cells, plastic, and human small intestines by Escherichia coli isolated from patients with diarrhea.

The Journal of infectious diseases·1992
Same journal

The balance between a new Antibiotic and Non-antibiotic Alternatives for the treatment and prevention of uncomplicated Urinary Tract Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Understanding the Clone-Censor-Weight Method in Observational Studies of Antibiotic Duration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Protection Against Recurrent Typhoid Fever Conferred by a Prior Episode: Evidence from a Large Cohort Study in Dhaka, Bangladesh.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Low-risk neutropenic patients can receive outpatient oral antibiotics. High-risk patients require parenteral antibiotics, with specific agents for Gram-positive infections and methicillin-resistant Staphylococcus aureus.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Pharmacology

Background:

  • Neutropenia, a low white blood cell count, increases infection risk.
  • Prompt and appropriate antibiotic selection is crucial for neutropenic patients.

Purpose of the Study:

  • To outline current antibiotic strategies for neutropenic patients.
  • To differentiate treatment approaches based on patient risk and pathogen.

Main Methods:

  • Review of existing guidelines and literature on neutropenic fever management.
  • Categorization of treatment based on risk stratification (low vs. high).

Main Results:

  • Oral ciprofloxacin or levofloxacin for low-risk outpatient management.
  • Parenteral cefepime or carbapenems for high-risk patients.

Related Experiment Videos

  • Vancomycin or teicoplanin for methicillin-resistant Staphylococcus aureus (MRSA).

    • Conclusions:

    • Treatment duration typically involves defervescence for at least 7 days.
    • Reassessment and potential antibiotic escalation are necessary for persistent fever.
    • Specific recommendations for modifying antibiotic regimens based on clinical response.